NCT00436566 - Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

March 16, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

July 22, 2019

Conditions

Breast CancerCardiac Toxicity

Interventions

BIOLOGICAL

trastuzumab

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

lapatinib ditosylate

DRUG

paclitaxel

GENETIC

gene expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

fluorophotometry

OTHER

laboratory biomarker analysis

OTHER

mass spectrometry

PROCEDURE

adjuvant therapy

PROCEDURE

quality-of-life assessment

Trial Locations (1)

Mayo Clinic Cancer Research Consortium, Rochester